Lauper's psoriasis awareness campaign tops weekly dermatology reads

Pop star Cyndi Lauper’s partnership with the National Psoriasis Foundation and Novartis Pharmaceuticals on a national psoriasis awareness campaign was the top-read article of the past week on Healio.com/Dermatology.

Other widely read articles focused on patients with psoriasis being at increased risk for developing arrhythmia and the recent FDA approval of Odomzo for treating locally advanced basal cell carcinoma.

Cyndi Lauper partners on ‘I’m PsO Ready’ psoriasis awareness campaign

Cyndi Lauper has partnered with the National Psoriasis Foundation and Novartis Pharmaceuticals on a national awareness campaign called “I’m PsO Ready,” which will focus on physical, emotional and social challenges of psoriasis.

Cyndi Lauper

As part of the campaign, Lauper reveals her struggle with psoriasis. Read more

Patients with psoriasis, psoriatic arthritis at greater risk for developing arrhythmia

Patients with psoriasis, and particularly those with psoriatic arthritis, were at increased risk for developing arrhythmia, independent of traditional cardiovascular risk factors, according to study results.

Researchers conducted a population-based cohort study and used the Taiwan Health Insurance Research Database to identify 40,367 patients with psoriasis and 162,548 people without psoriasis from 2004 to 2006. Read more

Xeljanz may reduce atopic dermatitis symptoms

Patients with moderate-to-severe atopic dermatitis treated with Xeljanz showed reductions in disease signs and symptoms in a recent study.

Brett A. King

Brett A. King, MD, PhD, assistant professor of dermatology, Yale School of Medicine, and colleagues studied six adults (aged 18 to 55 years) with moderate-to-severe atopic dermatitis who were treated with Xeljanz (tofacitinib citrate, Pfizer) after failing standard therapy. Read more

FDA grants orphan drug status to Humira for treatment of hidradenitis suppurativa

AbbVie announced that the FDA has granted orphan drug designation to Humira for treating moderate-to-severe hidradenitis suppurativa.

The supplemental biologic license application by AbbVie seeks the agency’s approval for the use of Humira (adalimumab) in patients with moderate-to-severe hidradenitis suppurativa (Hurley Stage II and Hurley Stage III disease), according to a press release. Read more

FDA approves Odomzo for locally advanced basal cell carcinoma

The FDA announced the approval of Odomzo for the treatment of patients with locally advanced basal cell carcinoma.

Odomzo (sonidegib, Novartis Pharmaceuticals) is indicated for patients whose basal cell carcinoma has advanced despite surgery or radiation therapy, or for patients who are not candidates for surgery or radiation. Read more